Implications of NRAS mutations in AML: A study of 2502 patients

Blood

Volumn 107, Issue 10, 2006, Pages 3847-3853

  Bacher, Ulrike ^b   Haferlach, Torsten ^b   Schoch, Claudia ^b   Kern, Wolfgang ^b   Schnittger, Susanne ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL;

EID: 33646575624     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3522     Document Type: Article

References (46)

1. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002;39:6-11.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
3. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBP alpha), in acute myeloid leukemia. Nat Genet. 2001;27:263-270.
4. Frohling S, Schlenk RE, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624-633.
5. Roumier C, Eclache V, Imbert M, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood. 2003;101:1277-1283.
6. Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100:2393-2398.
7. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59-66.
8. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
9. Schnittger S, Kohl T, Haferlach T, et al. KIT-D816 mutations in AML1-ETO positive AML are associated with impaired event-free and overall survival. Blood. Prepublished on October 27, 2005, as DOI 10.1182/blood-2005-04-1466.
10. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14:796-804.
11. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20:3254-3261.
12. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37:237-251.
13. Schnittger S, Schoch CW, Mecucci C, et al. Nucleophosmin gene mutations are predictors of favoable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733-3739.
14. Verhhaak RG, Goodswaard CS, Van Putten W, Bijl MA, Valk PJM. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747-3754.
15. Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the Ras protooncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603-1611.
16. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
17. Stirewalt. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia [published correction appears in Blood. 2001;98:924]. Blood. 2001;97:3589-3595.
18. Illmer T, Thiede C, Fredersdorf A, et al. Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res. 2005;11:3217-3224.
19. Bowen D, Frew M, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106:2113-2119.
20. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17:1071-1079.
21. Radich JP, Kopecky KJ, Willman CL, et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood. 1990;76:801-807.
22. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 of the N-Ras gene in acute myeloid leukemia. Leukemia. 1994;8:1682-1687.
23. Bos JL, Verlaandevries M, Vandereb AJ, et al. Mutations in N-Ras predominate in acute myeloid leukemia. Blood. 1987;69:1237-1241.
24. Toksoz D, Farr CJ, Marshall CJ. Ras-gene activation in a minor proportion of the blast population in acute myeloid leukemia. Oncogene. 1987;1:409-413.
25. Padua RA, West RR. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol. 2000;111:873-874.
26. Paquette RL, Landaw EM, Pierre RV, et al. N-Ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 1993;82:590-599.
27. Reilly JT. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis? Br J Haematol. 2005;128:18-34.
28. Valk PJM, Bowen DT, Frew ME, et al. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16) [abstract]. Haematologica. 2004;89:106.
29. Haferlach T, Kern W, Schoch C, Hiddemann W, Sauerland MC. Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia [reply]. J Clin Oncol. 2003;21:3004-3005.
30. Schnittger S, Weisser M, Schoch C, et al. New score predicting for prognosis in PML-RARA(+), AML1-ETO+, or CBFB-MYH11(+) acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102:2746-2755.
31. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120-125.
32. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
33. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
34. Nakao M, Janssen JWG, Seriu T, Bartram CR. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis: LightCycler technology. Leukemia. 2000;14:312-315.
35. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am J Stat Assoc. 1958;53:457-481.
36. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 2005;65:9152-9154.
37. Schoch, C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005;43:227-238.
38. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
39. Panagopoulos I, Aman P, Johansson B, et al. NRAS mutations are rare in acute myeloid leukaemias with t(8;21) or inv(16). Eur J Haematol. 1996;56:68-71.
40. Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106:3768-3776.
41. Kuchenbauer F, Schoch C, Kern W, et al. Impact of FLT3 mutations and promyelocytic leukaemiabreakpoint on clinical characteristics and prognosis in acute promyeocytic leukaemia. Br J Haematol. 2005;130:196-202.
42. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/ overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A. 2005;102:1104-1109.
43. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157-162.
44. Gilliland DG. Editorial commentary: hematologic malignancies. Curr Opin Hematol. 2001;8:189-191.
45. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
46. Care RS, Valk PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121:775-777.